Carcinoma, Hepatocellular: all 3,251 studies

Page 19 of 33. Open to participants first (976), then studies with results posted, then the rest; newest registration first within each.

• A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).Status unknownNCT04826406Phase 2
• Perception of the Doctor/Patient Relationship, Disease and Treatment Among Physicians and Their Patients Treated With Systemic Therapy for Hepatocellular Carcinoma "PERCEPTION1"CompletedNCT04823754
• Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW ComparisonCompletedNCT04823715
• Surgical Therapy and Survival in HCC/ C.F. Zhang et al.CompletedNCT04820712
• PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical TrialStatus unknownNCT04814043Phase 2
• Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical TrialStatus unknownNCT04814030Phase 2
• Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External RadiationCompletedNCT04813861
• A Dose Escalation Study of LNA-i-Mir-221 for Cancer TreatmentCompletedNCT04811898Phase 1
• Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）Status unknownNCT04806243Phase 2
• Stereotactic Body Proton Radiotherapy for the Treatment of Liver CancerTerminatedNCT04805788Phase 2
• "No-Touch" Radiofrequency Ablation for Small Hepatocellular Carcinoma (≤ 3cm): A Prospective Multicenter StudyTerminatedNCT04803890Not applicable
• Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular CarcinomaStatus unknownNCT04803019Phase 3
• Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk PatientsCompletedNCT04802954Not applicable
• TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical StudyStatus unknownNCT04796025Phase 2
• PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCCActive, not recruitingNCT04792801
• Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular CarcinomaActive, not recruitingNCT04791735Not applicable
• Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCCCompletedNCT04791176Phase 2
• Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver CirrhosisActive, not recruitingNCT04785534Not applicable
• Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid MalignanciesTerminatedNCT04785287Phase 1/2
• Balloon Assisted Transarterial Therapy for Hepatocellular CarcinomaCompletedNCT04780802Not applicable
• Volumetric Analysis of Hepatocellular Carcinoma After Transarterial ChemoembolizationCompletedNCT04780789
• Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7TerminatedNCT04777851Phase 3
• BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver CancerTerminatedNCT04777708Early Phase 1
• A Study to Evaluate Vaccines Against COVID-19 in the Real WorldWithdrawnNCT04775056
• Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade LymphomasStatus unknownNCT04773769Not applicable
• Radioembolization for Hepatocellular Carcinoma With Portal Vein Tumoral ThrombosisCompletedNCT04771988
• Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 InhibitorsCompletedNCT04767906Phase 2
• Role of LncRNA H19 in The Regulation of IGF-1R ExpressionCompletedNCT04767750
• Netrin-1 & Hepatocellular Carcinoma HCCStatus unknownNCT04766736
• Serum Visfatin and Serum Vaspin in Patients With Hepatocellular Carcinoma on Top of Liver CirrhosisCompletedNCT04763707
• A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular CarcinomaCompletedNCT04763408
• Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04741165Phase 2
• Trans-arterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Study of Different Outcomes and Their Predictive FactorsStatus unknownNCT04739501
• ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable orStatus unknownNCT04730388
• A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedNCT04728321Phase 2
• Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II TrialActive, not recruitingNCT04727307Phase 2
• Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular CarcinomaStatus unknownNCT04724226Phase 2
• Low Contrast Agent and Radiation Dose Protocol for Liver CT in Patients With HCCCompletedNCT04722120Not applicable
• Combined Therapy for Hepatocellular Carcinoma >3-<5 cmCompletedNCT04721470Not applicable
• Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver CancerActive, not recruitingNCT04721132Phase 2
• A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCCCompletedNCT04720716Phase 3
• Blood Sample Collection for Experimental Blood Test to Track Liver CancerCompletedNCT04720430
• Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCCStatus unknownNCT04718909Phase 2
• CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular CarcinomaStatus unknownNCT04715321
• A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Phase 3
• Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib AloneCompletedNCT04710641Phase 2
• Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma with PVTTTerminatedNCT04709380Phase 3
• Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial RadioembolizationTerminatedNCT04702230
• Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaCompletedNCT04701060Phase 2
• Investigation of Immune Modulation by Modern Acupuncture in Gastroenterologic CancersCompletedNCT04692454Not applicable
• Multimodal Machine Learning Characterization of Solid TumorsCompletedNCT04687969
• Comparison of Multiphase and Monophasic Arterial Hepatic MRI in the Detection of Arterial Enhancement of CHC NodulesCompletedNCT04687280
• Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 TrialStatus unknownNCT04687163Phase 3
• Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic CancersActive, not recruitingNCT04682847
• Phenotyping Liver Cancer RegistryCompletedNCT04681274
• TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver TransplantationStatus unknownNCT04677088Phase 1
• Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard TherapyCompletedNCT04676633Phase 1
• HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority TrialStatus unknownNCT04667351Phase 3
• IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCCStatus unknownNCT04665362Phase 1
• CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsActive, not recruitingNCT04660929Phase 1
• Nurse-led Decision Counseling on Hepatocellular Carcinoma ScreeningCompletedNCT04659005Not applicable
• Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04658147Phase 1
• HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled TrialCompletedNCT04653818Phase 4
• Safety and Efficacy of DEB-TACE Performed With a Novel Reflux-control Microcatheter in Patients With HCCStatus unknownNCT04653701
• Perioperative Therapy for Hepatocellular CarcinomaTerminatedNCT04653389Phase 2
• MR Quality + Diagnostic Performance for CHC Diagnosis - Gadoxetic Acid, Gadoteric Acid and P03277 ComparisonCompletedNCT04652947
• Tislelizumab in Combination With TACE in Advanced Hepatocellular CarcinomaStatus unknownNCT04652492Phase 2
• Ablation Combined With PD-1 in HCC: Phase II StudyStatus unknownNCT04652440Phase 1/2
• The Effect of Mobile Health-based Exercise on Hepatocellular Carcinoma Patients With Insulin ResistanceTerminatedNCT04649671Not applicable
• Study of Entecavir for Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B PatientsStatus unknownNCT04646928
• Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular CarcinomaCompletedNCT04642547Not applicable
• Substudy: Interconnection of Arterial Tumor Feeders Through Tumor Sinusoid in HCCCompletedNCT04641637Not applicable
• Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCCStatus unknownNCT04639284
• A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationActive, not recruitingNCT04639180Phase 3
• Observational Study on Patients With Hepatobiliary TumorsStatus unknownNCT04637048
• A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular CarcinomaTerminatedNCT04635527Phase 1
• Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular CarcinomaCompletedNCT04627012
• Volatile Organic Compounds for the Assessment of Liver DiseaseCompletedNCT04620538
• Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)Status unknownNCT04619342Not applicable
• Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in Treatment of Huge Hepatocellular Carcinoma (HCC) (≥10cm)Status unknownNCT04619329Not applicable
• HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTTCompletedNCT04618367Not applicable
• SynOV1.1 Intratumoral Injection StudyStatus unknownNCT04612504Phase 1
• Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCCCompletedNCT04611165Phase 2
• Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver CancerActive, not recruitingNCT04605731Phase 1
• Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT04605185Phase 1
• The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric CancerCompletedNCT04602026Not applicable
• Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma PatientsStatus unknownNCT04601961Not applicable
• KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular CarcinomaTerminatedNCT04601610Phase 1/2
• Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)TerminatedNCT04601428Early Phase 1
• TACE Combined With Lenvatinib and Sintilimab for Advanced HCCCompletedNCT04599790Phase 2
• TACE Combined With Sorafenib and Tislelizumab for Advanced HCCCompletedNCT04599777Phase 2
• TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCCStatus unknownNCT04597970Phase 2
• INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsCompletedNCT04580485Phase 1
• Comparison of Criteria for Liver Transplantation in Hepatocellular CarcinomaCompletedNCT04576572
• Prevention of Hand-foot Skin ReactionCompletedNCT04568330Not applicable
• Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver TransplantationStatus unknownNCT04564313Phase 1
• An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)Active, not recruitingNCT04563338Phase 2
• The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled TrialCompletedNCT04562428Phase 4
• SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular CarcinomaActive, not recruitingNCT04560894Phase 2/3
• TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)Status unknownNCT04560751

← Carcinoma, Hepatocellular overview